- Home
- ANAB vs SNCY Comparison
ANAB vs SNCY Comparison
Compare ANAB & SNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- SNCY
- Stock Information
- Founded
- ANAB 2005
- SNCY 1982
- Country
- ANAB United States
- SNCY United States
- Employees
- ANAB N/A
- SNCY N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- SNCY Air Freight/Delivery Services
- Sector
- ANAB Health Care
- SNCY Consumer Discretionary
- Exchange
- ANAB Nasdaq
- SNCY Nasdaq
- Market Cap
- ANAB 659.6M
- SNCY 634.5M
- IPO Year
- ANAB 2017
- SNCY 2021
- Fundamental
- Price
- ANAB $31.83
- SNCY $11.62
- Analyst Decision
- ANAB Buy
- SNCY Buy
- Analyst Count
- ANAB 10
- SNCY 6
- Target Price
- ANAB $50.63
- SNCY $18.50
- AVG Volume (30 Days)
- ANAB 749.6K
- SNCY 1.1M
- Earning Date
- ANAB 11-04-2025
- SNCY 10-29-2025
- Dividend Yield
- ANAB N/A
- SNCY N/A
- EPS Growth
- ANAB N/A
- SNCY 20.75
- EPS
- ANAB N/A
- SNCY 1.07
- Revenue
- ANAB $123,164,000.00
- SNCY $1,100,145,000.00
- Revenue This Year
- ANAB $11.40
- SNCY $5.97
- Revenue Next Year
- ANAB $8.17
- SNCY $10.61
- P/E Ratio
- ANAB N/A
- SNCY $10.73
- Revenue Growth
- ANAB 304.17
- SNCY 3.76
- 52 Week Low
- ANAB $12.21
- SNCY $8.10
- 52 Week High
- ANAB $36.54
- SNCY $18.59
- Technical
- Relative Strength Index (RSI)
- ANAB 71.43
- SNCY 37.96
- Support Level
- ANAB $29.49
- SNCY $11.18
- Resistance Level
- ANAB $32.24
- SNCY $12.11
- Average True Range (ATR)
- ANAB 2.08
- SNCY 0.43
- MACD
- ANAB 0.81
- SNCY -0.13
- Stochastic Oscillator
- ANAB 82.04
- SNCY 9.14
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About SNCY Sun Country Airlines Holdings Inc.
Sun Country Airlines Holdings Inc operates low-cost air carriers. The business has two operating segments: Passenger and Cargo. The passenger segment has two internal passenger groups Scheduled service and Charter. The Cargo segment provides air cargo services. The majority of the revenue is from the passenger segment.